Patents by Inventor Dominick J Laddy

Dominick J Laddy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant Cytomegalovirus Vectors As Vaccines For Tuberculosis
    Publication number: 20240150789
    Abstract: The present disclosure provides cytomegalovirus vectors encoding fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
    Type: Application
    Filed: October 27, 2023
    Publication date: May 9, 2024
    Inventors: Thomas G. Evans, Ravi Anantha, Aurelio M. Bonavia, Dominick J. Laddy, Louis Picker, Scott Hansen, Guangwu Xu
  • Recombinant cytomegalovirus vectors as vaccines for tuberculosis
    Patent number: 11834669
    Abstract: Disclosed herein are cytomegalovirus vectors encoding fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: December 5, 2023
    Assignees: International AIDS Vaccine Initiative, Inc., Oregon Health and Science University
    Inventors: Thomas G. Evans, Ravi Anantha, Aurelio M. Bonavia, Dominick J. Laddy, Louis Picker, Scott Hansen, Guangwu Xu
  • Recombinant Cytomegalovirus Vectors As Vaccines For Tuberculosis
    Publication number: 20210403951
    Abstract: The present disclosure provides cytomegalovirus vectors encoding fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
    Type: Application
    Filed: July 1, 2021
    Publication date: December 30, 2021
    Inventors: Thomas G. Evans, Ravi Anantha, Aurelio M. Bonavia, Dominick J. Laddy, Louis Picker, Scott Hansen, Guangwu Xu
  • Recombinant cytomegalovirus vectors as vaccines for tuberculosis
    Patent number: 11091775
    Abstract: The present disclosure provides cytomegalovirus vectors encoding fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: August 17, 2021
    Assignees: Oregon Health and Science University, International AIDS Vaccine Initative, Inc.
    Inventors: Thomas G. Evans, Ravi P. Anantha, Aurelio M. Bonavia, Dominick J. Laddy, Louis Picker, Scott Hansen, Guangwu Xu
  • Recombinant Cytomegalovirus Vectors As Vaccines For Tuberculosis
    Publication number: 20180016599
    Abstract: The present disclosure provides cytomegalovirus vectors encoding fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
    Type: Application
    Filed: June 21, 2017
    Publication date: January 18, 2018
    Inventors: Thomas G. Evans, Ravi P. Anantha, Aurelio M. Bonavia, Dominick J. Laddy, Louis Picker, Scott Hansen, Guangwu Xu
  • Vaccines against multiple subtypes of influenza virus
    Patent number: 8133723
    Abstract: An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein the consensus influenza antigen comprises consensus hemagglutinin (HA), neuraminidase (NA), matrix protein, nucleoprotein, M2 ectodomain-nucleo-protein (M2e-NP), or a combination thereof. Preferably the consensus influenza antigen comprises HA, NA, M2e-NP, or a combination thereof. The DNA plasmid comprises a promoter operably linked to a coding sequence that encodes the consensus influenza antigen. Additionally, an aspect of the present invention includes methods of eliciting an immune response against a plurality of influenza virus subtypes in a mammal using the DNA plasmid vaccines provided.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: March 13, 2012
    Assignee: The Trustees of The University of Pennsylvania
    Inventors: Ruxandra Draghia-Akli, David B Weiner, Jian Yan, Dominick J Laddy